150,000 patients tracked: does finerenone protect hearts in kidney disease and diabetes?
NCT ID NCT06608212
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This observational study follows 150,000 people with chronic kidney disease and type 2 diabetes to see how finerenone (Kerendia) works in everyday medical care. Researchers will compare those taking finerenone to those not taking it, looking at rates of heart attacks and heart failure hospitalizations. No extra visits or tests are required—only existing health records are used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
finerenone (Kerendia)
What this could lead to
If successful, this study could confirm that finerenone is safe and effective for preventing heart attacks and heart failure hospitalizations in real-world patients with CKD and T2D.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It only looks at existing data, so it cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bayer
Whippany, New Jersey, 07981, United States